These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36209344)
21. Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma. Zhu YJ; Xu Q; Shao MY; Cao XY; Wu ZR; Chen YW; Bu H; Shi YJ Hepatobiliary Pancreat Dis Int; 2019 Oct; 18(5):464-470. PubMed ID: 31402267 [TBL] [Abstract][Full Text] [Related]
22. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma. Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813 [TBL] [Abstract][Full Text] [Related]
23. DAGLβ is the principal synthesizing enzyme of 2-AG and promotes aggressive phenotype of intrahepatic cholangiocarcinoma via AP-1/DAGLβ/miR4516 feedforward circuitry. Ma M; Zeng G; Tan B; Zhao G; Su Q; Zhang W; Song Y; Liang J; Xu B; Wang Z; Chen J; Hou M; Yang C; Yun J; Huang Y; Lin Y; Chen D; Han Y; DeMorrow S; Liang L; Lai J; Huang L Am J Physiol Gastrointest Liver Physiol; 2023 Sep; 325(3):G213-G229. PubMed ID: 37366545 [TBL] [Abstract][Full Text] [Related]
24. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127 [TBL] [Abstract][Full Text] [Related]
25. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway. Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057 [TBL] [Abstract][Full Text] [Related]
26. Calcium-sensing receptor promotes tumor proliferation and migration in human intrahepatic cholangiocarcinoma by targeting ERK signaling pathway. Fang Y; Liu L; Liu S; Hu L; Cai W; Wan X; Liu D; He Y; Zhu Z Eur J Pharmacol; 2020 Apr; 872():172915. PubMed ID: 31926993 [TBL] [Abstract][Full Text] [Related]
27. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704 [TBL] [Abstract][Full Text] [Related]
28. Integrative epigenomic profiling reveal AP-1 is a key regulator in intrahepatich cholangiocarcinoma. He K; Feng Y; An S; Liu F; Xiang G Genomics; 2022 Jan; 114(1):241-252. PubMed ID: 34942351 [TBL] [Abstract][Full Text] [Related]
29. Peroxiredoxin 6 Inhibits Osteogenic Differentiation and Bone Formation Through Human Dental Pulp Stem Cells and Induces Delayed Bone Development. Park KR; Yun HM; Yeo IJ; Cho S; Hong JT; Jeong YS Antioxid Redox Signal; 2019 Jun; 30(17):1969-1982. PubMed ID: 29792351 [No Abstract] [Full Text] [Related]
30. Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues. Chen BD; Zhao WC; Dong JD; Sima H Mol Biol Rep; 2014 Jul; 41(7):4313-20. PubMed ID: 24577752 [TBL] [Abstract][Full Text] [Related]
35. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. Kawahigashi Y; Mishima T; Mizuguchi Y; Arima Y; Yokomuro S; Kanda T; Ishibashi O; Yoshida H; Tajiri T; Takizawa T J Nippon Med Sch; 2009 Aug; 76(4):188-97. PubMed ID: 19755794 [TBL] [Abstract][Full Text] [Related]
36. A high level of integrin α6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype. Ding YB; Deng B; Huang YS; Xiao WM; Wu J; Zhang YQ; Wang YZ; Wu DC; Lu GT; Wu KY Dig Dis Sci; 2013 Jun; 58(6):1627-35. PubMed ID: 23306848 [TBL] [Abstract][Full Text] [Related]
37. Anti-cancer effect of thiacremonone through down regulation of peroxiredoxin 6. Jo M; Yun HM; Park KR; Park MH; Lee DH; Cho SH; Yoo HS; Lee YM; Jeong HS; Kim Y; Jung JK; Hwang BY; Lee MK; Kim ND; Han SB; Hong JT PLoS One; 2014; 9(3):e91508. PubMed ID: 24618722 [TBL] [Abstract][Full Text] [Related]
38. VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization. Xu H; Lin X; Li Z; He X; Li Y; Qiu L; Lu L; Liu B; Zhan M; He K J Gastroenterol; 2023 Sep; 58(9):925-944. PubMed ID: 37391589 [TBL] [Abstract][Full Text] [Related]
39. H2O2-dependent hyperoxidation of peroxiredoxin 6 (Prdx6) plays a role in cellular toxicity via up-regulation of iPLA2 activity. Kim SY; Jo HY; Kim MH; Cha YY; Choi SW; Shim JH; Kim TJ; Lee KY J Biol Chem; 2008 Nov; 283(48):33563-8. PubMed ID: 18826942 [TBL] [Abstract][Full Text] [Related]
40. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis. Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]